Literature DB >> 11144450

Tuberculosis in Russia.

M I Perelman1.   

Abstract

Various aspects of tuberculosis in Russia, including epidemiology, means of prevention, diagnosis and treatment, have been widely discussed in the last few years in the medical literature and by the general media. A certain amount of controversy has been generated on some of these subjects. This review is an attempt to objectively analyze the true situation of tuberculosis in Russia, including the issues of control measures, as viewed by the public health authorities and by the majority of Russian tuberculosis specialists. The data presented and their analysis reflect the official position of the Russian Federation Ministry of Health. These views became a basis for the concept of the national anti-tuberculosis program to serve the needs of the population, which was approved by the Scientific Council of the Ministry of Health of Russia in February 2000.

Entities:  

Mesh:

Year:  2000        PMID: 11144450

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  14 in total

1.  High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001.

Authors:  Igor Mokrousov; Olga Narvskaya; Tatiana Otten; Elena Limeschenko; Lidia Steklova; Boris Vyshnevskiy
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Epidemiology, diagnostic possibilities, and treatment of tuberculosis.

Authors:  R Kurth; W H Haas
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 3.  Surgical treatment of drug-resistant tuberculosis.

Authors:  Russell R Kempker; Sergo Vashakidze; Nelly Solomonia; Nino Dzidzikashvili; Henry M Blumberg
Journal:  Lancet Infect Dis       Date:  2012-02       Impact factor: 25.071

4.  Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia.

Authors:  Olga S Toungoussova; Per Sandven; Andrey O Mariandyshev; Nina I Nizovtseva; Gunnar Bjune; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Health in financial crises: economic recession and tuberculosis in Central and Eastern Europe.

Authors:  Nimalan Arinaminpathy; Christopher Dye
Journal:  J R Soc Interface       Date:  2010-04-28       Impact factor: 4.118

6.  Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe.

Authors:  M Mansfeld; A Skrahina; L Shepherd; A Schultze; A M Panteleev; R F Miller; J M Miro; I Zeltina; S Tetradov; H Furrer; O Kirk; A Grzeszczuk; N Bolokadze; A Matteelli; F A Post; J D Lundgren; A Mocroft; Amw Efsen; D N Podlekareva
Journal:  HIV Med       Date:  2015-05-11       Impact factor: 3.180

7.  Impact of drug-resistant Mycobacterium tuberculosis on treatment outcome of culture-positive cases of tuberculosis in the Archangel oblast, Russia, in 1999.

Authors:  O S Toungoussova; N I Nizovtseva; A O Mariandyshev; D A Caugant; P Sandven; G Bjune
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

8.  Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing.

Authors:  Igor Mokrousov; Tatiana Otten; Boris Vyshnevskiy; Olga Narvskaya
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

9.  Allele-specific rpoB PCR assays for detection of rifampin-resistant Mycobacterium tuberculosis in sputum smears.

Authors:  Igor Mokrousov; Tatiana Otten; Boris Vyshnevskiy; Olga Narvskaya
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis.

Authors:  Francine Matthys; Leen Rigouts; Vinciane Sizaire; Natalia Vezhnina; Maryvonne Lecoq; Vera Golubeva; Françoise Portaels; Patrick Van der Stuyft; Michael Kimerling
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.